W P Peters

Author PubWeight™ 67.25‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Sequential prophylactic oral and empiric once-daily parenteral antibiotics for neutropenia and fever after high-dose chemotherapy and autologous bone marrow support. J Clin Oncol 1994 2.14
2 Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med 1988 1.67
3 A randomized phase III comparative trial of immediate consolidation with high-dose chemotherapy and autologous peripheral blood progenitor cell support compared to observation with delayed consolidation in women with metastatic breast cancer and only bone metastases following intensive induction chemotherapy. Bone Marrow Transplant 2006 1.66
4 Pressor effect of naloxone in septic shock. Lancet 1981 1.53
5 Transforming growth factor beta as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. N Engl J Med 1993 1.45
6 Retinopathy and optic neuropathy in bone marrow transplantation for breast cancer. Ophthalmology 1996 1.44
7 Randomized trial of high-dose chemotherapy with autologous bone marrow support as adjuvant therapy for high-risk, multi-node-positive malignant melanoma. J Natl Cancer Inst 1993 1.40
8 Physician-assisted suicide and advance directives concerning life support. N C Med J 1993 1.39
9 High-dose chemotherapy and autologous stem cell transplantation for breast cancer. Cancer Invest 2000 1.37
10 Evidence for RNA tumor viruses in human lymphomas including Burkitt's disease. Cancer Res 1973 1.19
11 Corticosteroid administration and localized leukocyte mobilization in man. N Engl J Med 1972 1.05
12 Characterisation of a virus (HL23V) isolated from cultured acute myelogenous leukaemic cells. Nature 1976 1.01
13 Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support. J Clin Oncol 1999 0.96
14 Expression of interleukin-1 alpha, interleukin-1 beta, and an interleukin-1 receptor antagonist in human retinal pigment epithelial cells. Exp Eye Res 1992 0.96
15 Pharmacokinetics and immediate effects of high-dose carmustine in man. Cancer Treat Rep 1986 0.95
16 Stimulation of ovarian tumor cell proliferation with monocyte products including interleukin-1, interleukin-6, and tumor necrosis factor-alpha. Am J Obstet Gynecol 1992 0.94
17 Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. J Infect Dis 1992 0.94
18 Clinical and pharmacological phase I evaluation of Exherin (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing solid tumours. Ann Oncol 2009 0.93
19 Biological and biochemical evidence for an interaction between Marek's disease herpesvirus and avian leukosis virus in vivo. Proc Natl Acad Sci U S A 1973 0.91
20 Pulmonary drug toxicity in patients with primary breast cancer treated with high-dose combination chemotherapy and autologous bone marrow transplantation. Am Rev Respir Dis 1993 0.89
21 Unique nuclear DNA sequences in the involved tissues of Hodgkin's and Burkitt's lymphomas. Proc Natl Acad Sci U S A 1973 0.89
22 Elimination of malignant clonogenic breast cancer cells from human bone marrow. Cancer Res 1989 0.88
23 Synergistic cytotoxicity of different alkylating agents for epithelial ovarian cancer. Int J Cancer 1991 0.86
24 Characterization of endogenous cytokine concentrations after high-dose chemotherapy with autologous bone marrow support. Blood 1993 0.85
25 Thrombotic microangiopathy as a complication of high-dose chemotherapy for breast cancer. Bone Marrow Transplant 1996 0.85
26 Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer. Cancer Chemother Pharmacol 1998 0.84
27 Myocardial ischemia associated with high-dose carmustine infusion. Cancer 1991 0.84
28 Response of drug-sensitive and -resistant L1210 leukemias to high-dose chemotherapy. Cancer Res 1987 0.83
29 Modulation of macrophage colony stimulating factor in cultured human retinal pigment epithelial cells. Exp Eye Res 1992 0.82
30 Cost analysis of pancreatic carcinoma treatment. Cancer 2000 0.82
31 A randomized trial of recombinant human interleukin-11 following autologous bone marrow transplantation with peripheral blood progenitor cell support in patients with breast cancer. Biol Blood Marrow Transplant 1998 0.82
32 Measurement of busulfan in plasma by high-performance liquid chromatography. J Chromatogr 1987 0.82
33 The significance of tumor contamination in the bone marrow from high-risk primary breast cancer patients treated with high-dose chemotherapy and hematopoietic support. Biol Blood Marrow Transplant 1997 0.82
34 High-dose combination alkylating agents with autologous bone marrow support: a Phase 1 trial. J Clin Oncol 1986 0.81
35 Alterations in L-selectin expression and elastase activity in neutrophils from patients receiving granulocyte colony-stimulating factor alone or in conjunction with high-dose chemotherapy with autologous bone marrow transplantation. Lymphokine Cytokine Res 1994 0.81
36 High-dose combination alkylating agents with autologous bone-marrow support in patients with breast cancer: preliminary assessment of DNA damage in individual peripheral blood lymphocytes using the single cell gel electrophoresis assay. Mutat Res 1992 0.81
37 Randomized, double-blind comparison of a prochlorperazine-based versus a metoclopramide-based antiemetic regimen in patients undergoing autologous bone marrow transplantation. Cancer 1995 0.80
38 Changes in plasma transforming growth factor beta in response to high-dose chemotherapy for stage II breast cancer: possible implications for the prevention of hepatic veno-occlusive disease and pulmonary drug toxicity. Bone Marrow Transplant 1995 0.80
39 Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support. Blood 1994 0.80
40 Pharmacokinetics of dibromodulcitol in humans: a phase I study. J Clin Oncol 1986 0.80
41 A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignancies. Cancer Chemother Pharmacol 1996 0.80
42 Secondary myelodysplasia and acute leukemia in breast cancer patients after autologous bone marrow transplant. J Clin Oncol 1998 0.79
43 Protection against chemotherapy-induced alopecia by cyclosporin A in the newborn rat animal model. Dermatology 1995 0.79
44 Altered immunologic reconstitution after standard-dose chemotherapy or high-dose chemotherapy with autologous bone marrow support. Transplantation 1988 0.79
45 The analysis of relapse-free survival curves: implications for evaluating intensive systemic adjuvant treatment regimens for breast cancer. Br J Cancer 2005 0.79
46 Prevention of hemorrhagic cystitis after high-dose alkylating agent chemotherapy and autologous bone marrow support. Bone Marrow Transplant 1994 0.79
47 Pulmonary drug toxicity following high-dose chemotherapy with autologous bone marrow transplantation: CT findings in 20 cases. J Thorac Imaging 1994 0.79
48 Cardiac sequelae of doxorubicin and paclitaxel as induction chemotherapy prior to high-dose chemotherapy and peripheral blood progenitor cell transplantation in women with high-risk primary or metastatic breast cancer. Bone Marrow Transplant 2000 0.79
49 A phase I trial of recombinant human interleukin-1 beta (OCT-43) following high-dose chemotherapy and autologous bone marrow transplantation. Bone Marrow Transplant 1997 0.79
50 High-dose chemotherapy and hematopoietic stem cell transplantation for breast cancer: past or future? Semin Oncol 2001 0.79
51 Relation of glutathione S-transferase alpha and mu isoforms to response to therapy in human breast cancer. Clin Cancer Res 1997 0.79
52 Evaluation of symptom distress in a bone marrow transplant outpatient environment. Ann Pharmacother 1996 0.78
53 Autologous bone marrow transplantation and factor XII, factor VII, and protein C deficiencies. Report of a new association and its possible relationship to endothelial cell injury. Cancer 1990 0.78
54 Familial Burkitt's lymphoma. Association with altered lymphocyte subsets in family members. Am J Med 1986 0.78
55 Immunomagnetic purging of breast cancer from bone marrow for autologous transplantation. Bone Marrow Transplant 1991 0.78
56 Reduced mortality following bone marrow transplantation for breast cancer with the addition of peripheral blood progenitor cells is due to a marked reduction in veno-occlusive disease of the liver. Bone Marrow Transplant 1998 0.78
57 Cost implications of haematopoietic growth factors in the BMT setting. Bone Marrow Transplant 1993 0.78
58 Hematopoietic colony-stimulating factors and dose intensity. Semin Oncol 1993 0.77
59 A comparison of immunohistochemistry, two-color immunofluorescence, and flow cytometry with cell sorting for the detection of micrometastatic breast cancer in the bone marrow. J Hematother 1996 0.77
60 Measuring DNA damage in individual cells of heterogeneous mixtures: a novel application of an immunological typing technique. Mutat Res 1994 0.77
61 Recombinant human granulocyte-macrophage colony-stimulating factor produces fever. Lancet 1988 0.77
62 Breast cancer cells are effectively purged from peripheral blood progenitor cells with an immunomagnetic technique. Clin Cancer Res 1996 0.77
63 The addition of paclitaxel to continuous infusion 5-fluorouracil is an active regimen for metastatic breast cancer. Am J Clin Oncol 1998 0.77
64 Endogenous digoxin-like immunoreactive factor and digitalis-like factor associated with the hypertension of patients receiving multiple alkylating agents as part of autologous bone marrow transplantation. Clin Sci (Lond) 1989 0.77
65 High-dose chemotherapy and CD34-selected peripheral blood progenitor cell transplantation for patients with breast cancer metastatic to bone and/or bone marrow. Bone Marrow Transplant 2001 0.77
66 High-dose chemotherapy-induced platelet defect: inhibition of platelet signal transduction pathways. Mol Pharmacol 1993 0.77
67 Advances in the clinical use of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor to intensify cancer chemotherapy. Curr Opin Hematol 1994 0.76
68 Sequences related to the RNA tumor viruses in the RNA and DNA of human leukemias and lymphomas. Bibl Haematol 1975 0.76
69 High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience. Cancer Treat Rep 1987 0.76
70 The significance of microbial cultures of the hematopoietic support for patients receiving high-dose chemotherapy. J Hematother 1996 0.76
71 Malignant melanoma. Treatment with high-dose combination alkylating agent chemotherapy and autologous bone marrow support. Arch Dermatol 1988 0.76
72 Successful allogeneic bone marrow transplantation in selected patients over 50 years of age--a single institution's experience. Bone Marrow Transplant 1998 0.76
73 High-dose chemotherapy and autologous bone marrow support for breast cancer. Important Adv Oncol 1991 0.75
74 The use of growth factors with antibiotics in the setting of neutropenic fever. Am J Med 1996 0.75
75 Contributions from the American Medical Political Action Committee to members of Congress. N Engl J Med 1994 0.75
76 Modifying hematopoiesis with colony-stimulating factors. Am J Clin Pathol 1992 0.75
77 Prediction of the optimal timing of bone marrow reinfusion after high dose chemotherapy. Cancer Res 1986 0.75
78 Distribution of 99Tcm-sulphur colloid during granulocyte colony-stimulating factor administration in autologous bone marrow transplantation. Nucl Med Commun 1993 0.75
79 Hypertension and reversible myocardial depression associated with autologous bone marrow transplantation. Am J Med 1990 0.75
80 Detection of tumor cells in the bone marrow of stage IV breast cancer patients receiving high-dose chemotherapy: the role of induction chemotherapy. Bone Marrow Transplant 1995 0.75
81 Randomized, comparative study of high-dose (with autologous bone marrow support) versus low-dose cyclophosphamide, cisplatin, and carmustine as consolidation to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for patients with operable stage II or III breast cancer involving 10 or more axillary lymph nodes (CALGB Protocol 9082). Cancer and Leukemia Group B. J Natl Cancer Inst Monogr 1995 0.75
82 Guillain-Barre syndrome following autologous bone marrow transplantation. Am J Clin Oncol 1995 0.75
83 Effect of plasma TNF-alpha on filgrastim-stimulated hematopoiesis in mice and humans. Pharmacotherapy 1998 0.75
84 High-dose carboplatin, cyclophosphamide, and BCNU with autologous bone marrow support: excessive hepatic toxicity. Cancer Chemother Pharmacol 1990 0.75
85 Elimination of clonogenic breast cancer cells from human bone marrow. A comparison of immunotoxin treatment with chemoimmunoseparation using 4-hydroperoxycyclophosphamide, monoclonal antibodies, and magnetic microspheres. Cancer 1991 0.75
86 Elimination of malignant clonogenic T cells from human bone marrow using chemoimmunoseparation with 2'-deoxycoformycin, deoxyadenosine and an immunotoxin. Bone Marrow Transplant 1990 0.75
87 Phase-I trial of combination therapy with continuous-infusion MMPR and continuous-infusion 5-FU. Cancer Chemother Pharmacol 1984 0.75
88 Ocular toxicity following high dose chemotherapy and autologous transplant. Bone Marrow Transplant 1996 0.75
89 Retroviral gene transduction of circulating progenitor cells in patients with metastatic breast cancer. Surg Oncol 1993 0.75
90 Combined chemoseparation and immunoseparation of clonogenic T lymphoma cells from human bone marrow using 2'-deoxycoformycin, deoxyadenosine, 3A1 monoclonal antibody, and complement. Cancer Res 1987 0.75
91 A radiologic syndrome after high dose chemotherapy and autologous bone marrow transplantation, with clinical and pathologic features of systemic candidiasis. Cancer 1994 0.75
92 Detection of breast carcinoma cells in human bone marrow using fluorescence-activated cell sorting and conventional cytology. Am J Clin Pathol 1990 0.75
93 RNA tumor viruses and human lymphomas. Hamatol Bluttransfus 1974 0.75
94 The impact of conventional plus high dose chemotherapy with autologous bone marrow transplantation on hematologic toxicity during subsequent local-regional radiotherapy for breast cancer. Cancer 1994 0.75
95 Phase I study of recombinant human interleukin-1 beta (rhIL-1 beta) in patients with bone marrow failure. Bone Marrow Transplant 1994 0.75
96 Clinical pharmacology of filgrastim following high-dose chemotherapy and autologous bone marrow transplantation. Clin Cancer Res 1997 0.75
97 Contrasting characteristics of Marek's disease herpesvirus isolated from chickens with and without avian leukosis virus infection. Intervirology 1978 0.75
98 Changes in actin state and chemotactic peptide receptor expression in granulocytes during cytokine administration after autologous bone marrow transplantation. Lymphokine Cytokine Res 1992 0.75
99 Elevated endogenous serum macrophage colony-stimulating factor in the early stage of fungemia following bone marrow transplantation. Exp Hematol 1994 0.75
100 Impact of consolidation radiotherapy in patients with advanced breast cancer treated with high-dose chemotherapy and autologous bone marrow rescue. J Clin Oncol 1999 0.75
101 The pharmacologic effects of recombinant, human colony-stimulating factors and their modulation by theophylline. Pharmacotherapy 1997 0.75
102 Bone marrow and peripheral blood hematopoietic stem cell transplantation: focus on autografting. Clin Chem 2000 0.75
103 Reticulated platelet counts in patients undergoing autologous bone marrow transplantation: an aid in assessing marrow recovery. Am J Hematol 1994 0.75
104 Disposition of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving high-dose chemotherapy and autologous bone marrow support. Blood 1992 0.75
105 Autologous bone marrow transplantation in breast cancer. A panel discussion. Breast Cancer Res Treat 1988 0.75
106 Artifactual hypoglycemia associated with hematopoietic cytokines. Arch Pathol Lab Med 1995 0.75